Joseph Domachowske: Unmet needs in the prevention and treatment of respiratory syncytial virus in infants

Following the recent phase III and phase IIb data for nirsevimab in the treatment of respiratory syncytial virus (RSV), we were delighted to speak with Dr. Joseph Domachowske (Upstate University Hospital, Syracuse, NY, USA) to discuss the unmet needs in the prevention and treatment of RSV and the advantages of nirsevimab. 

Questions

1.  What are the unmet needs in the prevention and treatment of respiratory syncytial virus in infants? (00:15)
2. Could you tell us a little about nirsevimab and its advantages over other methods of prophylaxis? (01:10)

Disclosures: Joseph Domachowske discloses grant/research support from AstraZeneca.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.